Cofrogliptin

考格列汀

Report date: 2024/06/25 17:27:57
NME

Base Information

Drug NameCofrogliptin
Drug Alias Name倍长平HSK7653HSK-7653
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsGlucose IntoleranceDiabetes Mellitus, Type 2Renal Insufficiency
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSichuan Haisco Pharmaceutical Co LtdLiaoning Haisco Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesLiaoning Haisco Pharmaceutical Co LtdSichuan Haisco Pharmaceutical Co LtdHaisco Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsGlucose IntoleranceDiabetes Mellitus, Type 2Renal Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A